Literature DB >> 28611127

Pulmonary Hypertension Is Associated With a Higher Risk of Heart Failure Hospitalization and Mortality in Patients With Chronic Kidney Disease: The Jackson Heart Study.

Senthil Selvaraj1, Sanjiv J Shah2, Mark J Ommerborn2, Cheryl R Clark2, Michael E Hall2, Robert J Mentz2, Saadia Qazi2, Jeremy M Robbins2, Thomas N Skelton2, Jiaying Chen2, J Michael Gaziano2, Luc Djoussé2.   

Abstract

BACKGROUND: African Americans develop chronic kidney disease and pulmonary hypertension (PH) at disproportionately high rates. Little is known whether PH heightens the risk of heart failure (HF) admission or mortality among chronic kidney disease patients, including patients with non-end-stage renal disease. METHODS AND
RESULTS: We analyzed African Americans participants with chronic kidney disease (estimated glomerular filtration rate <60 mL/min per 1.73 m2 or urine albumin/creatinine >30 mg/g) and available echocardiogram-derived pulmonary artery systolic pressure (PASP) from the Jackson Heart Study (N=408). We used Cox models to assess whether PH (PASP>35 mm Hg) was associated with higher rates of HF hospitalization and mortality. In a secondary, cross-sectional analysis, we examined the relationship between cystatin C (a marker of renal function) and PASP and potential mediators, including BNP (B-type natriuretic peptide) and endothelin-1. In our cohort, the mean age was 63±13 years, 70% were female, 78% had hypertension, and 22% had PH. Eighty-five percent of the participants had an estimated glomerular filtration rate >30 mL/min per 1.73 m2. During follow-up, 13% were hospitalized for HF and 27% died. After adjusting for potential confounders, including BNP, PH was found to be associated with HF hospitalization (hazard ratio, 2.37; 95% confidence interval, 1.15-4.86) and the combined outcome of HF hospitalization or mortality (hazard ratio, 1.84; confidence interval, 1.09-3.10). Log cystatin C was directly associated with PASP (adjusted β =2.5 [95% confidence interval, 0.8-4.1] per standard deviation change in cystatin C). Mediation analysis showed that BNP and endothelin-1 explained 56% and 40%, respectively, of the indirect effects between cystatin C and PASP.
CONCLUSIONS: Among African Americans with chronic kidney disease, PH, which is likely pulmonary venous hypertension, was associated with a higher risk of HF admission and mortality.
© 2017 American Heart Association, Inc.

Entities:  

Keywords:  African American; chronic kidney disease; echocardiography; heart failure; pulmonary hypertension

Mesh:

Year:  2017        PMID: 28611127      PMCID: PMC5512446          DOI: 10.1161/CIRCHEARTFAILURE.116.003940

Source DB:  PubMed          Journal:  Circ Heart Fail        ISSN: 1941-3289            Impact factor:   8.790


  26 in total

Review 1.  Updated clinical classification of pulmonary hypertension.

Authors:  Gérald Simonneau; Ivan M Robbins; Maurice Beghetti; Richard N Channick; Marion Delcroix; Christopher P Denton; C Gregory Elliott; Sean P Gaine; Mark T Gladwin; Zhi-Cheng Jing; Michael J Krowka; David Langleben; Norifumi Nakanishi; Rogério Souza
Journal:  J Am Coll Cardiol       Date:  2009-06-30       Impact factor: 24.094

2.  Relations of left ventricular mass to demographic and hemodynamic variables in American Indians: the Strong Heart Study.

Authors:  R B Devereux; M J Roman; G de Simone; M J O'Grady; M Paranicas; J L Yeh; R R Fabsitz; B V Howard
Journal:  Circulation       Date:  1997-09-02       Impact factor: 29.690

Review 3.  Pulmonary hypertension in renal disease: epidemiology, potential mechanisms and implications.

Authors:  B Kawar; T Ellam; C Jackson; D G Kiely
Journal:  Am J Nephrol       Date:  2013-03-16       Impact factor: 3.754

4.  Pulmonary hypertension surveillance--United States, 1980-2002.

Authors:  Alexandra Hyduk; Janet B Croft; Carma Ayala; Kan Zheng; Zhi-Jie Zheng; George A Mensah
Journal:  MMWR Surveill Summ       Date:  2005-11-11

5.  Elevated pulmonary artery systolic pressure predicts heart failure admissions in African Americans: Jackson Heart Study.

Authors:  Gaurav Choudhary; Matthew Jankowich; Wen-Chih Wu
Journal:  Circ Heart Fail       Date:  2014-06-05       Impact factor: 8.790

6.  Reliability of echocardiographic assessment of left ventricular structure and function: the PRESERVE study. Prospective Randomized Study Evaluating Regression of Ventricular Enlargement.

Authors:  V Palmieri; B Dahlöf; V DeQuattro; N Sharpe; J N Bella; G de Simone; M Paranicas; D Fishman; R B Devereux
Journal:  J Am Coll Cardiol       Date:  1999-11-01       Impact factor: 24.094

7.  Prevalence, clinical phenotype, and outcomes associated with normal B-type natriuretic peptide levels in heart failure with preserved ejection fraction.

Authors:  Venkatesh Y Anjan; Timothy M Loftus; Michael A Burke; Nausheen Akhter; Gregg C Fonarow; Mihai Gheorghiade; Sanjiv J Shah
Journal:  Am J Cardiol       Date:  2012-06-07       Impact factor: 2.778

8.  Cardiovascular disease event classification in the Jackson Heart Study: methods and procedures.

Authors:  Emmanuel Keku; Wayne Rosamond; Herman A Taylor; Robert Garrison; Sharon B Wyatt; Michelle Richard; Brenda Jenkins; Lisa Reeves; Daniel Sarpong
Journal:  Ethn Dis       Date:  2005       Impact factor: 1.847

9.  Racial differences in plasma endothelin-1 concentrations in individuals with essential hypertension.

Authors:  S Ergul; D C Parish; D Puett; A Ergul
Journal:  Hypertension       Date:  1996-10       Impact factor: 10.190

10.  Pulmonary hypertension in patients with end-stage renal disease.

Authors:  Mordechai Yigla; Farid Nakhoul; Anat Sabag; Naveh Tov; Bella Gorevich; Ziad Abassi; Shimon A Reisner
Journal:  Chest       Date:  2003-05       Impact factor: 9.410

View more
  8 in total

1.  Association of Pulmonary Hypertension With Inflammatory Markers and Volume Status in Hemodialysis Patients of End-Stage Renal Disease.

Authors:  Satyendra K Sonkar; Mahboob Alam; Sharad Chandra; Gyanendra K Sonkar; Anil Gaikwad; Vivek Bhosale
Journal:  Cureus       Date:  2021-03-01

Review 2.  Diagnosis and Management of Pulmonary Hypertension in Patients With CKD.

Authors:  Carl P Walther; Vijay Nambi; Nicola A Hanania; Sankar D Navaneethan
Journal:  Am J Kidney Dis       Date:  2020-03-19       Impact factor: 8.860

3.  Prevalence of pulmonary hypertension in patients with chronic kidney disease without dialysis: a meta-analysis.

Authors:  Weifeng Shang; Yuanyuan Li; Yali Ren; Wei Li; HongLan Wei; Junwu Dong
Journal:  Int Urol Nephrol       Date:  2018-03-26       Impact factor: 2.370

4.  Incremental Utility of Right Ventricular Dysfunction in Patients With Myeloproliferative Neoplasm-Associated Pulmonary Hypertension.

Authors:  Jiwon Kim; Spencer Krichevsky; Lola Xie; Maria Chiara Palumbo; Sara Rodriguez-Diego; Brian Yum; Lillian Brouwer; Richard T Silver; Andrew I Schafer; Ellen K Ritchie; Maria Mia Yabut; Claudia Sosner; Evelyn M Horn; Richard B Devereux; Joseph M Scandura; Jonathan W Weinsaft
Journal:  J Am Soc Echocardiogr       Date:  2019-10-03       Impact factor: 5.251

5.  The Prevalence of Pulmonary Hypertension Among Maintenance Dialysis Patients With ESRD and Its Associated Factors: A Retrospective Study.

Authors:  Ying Zhang; Xiao-Han Ding; Rongsheng Rao; Yiqin Wang; Fang Pang; Sha Tang; Ling Nie; Shi-Zhu Bian
Journal:  Front Med (Lausanne)       Date:  2020-12-04

6.  Pulmonary hypertension in chronic kidney disease: a hemodynamic characterization.

Authors:  Thenappan Thenappan
Journal:  Pulm Circ       Date:  2017 Jul-Sep       Impact factor: 3.017

7.  Combination of peripheral blood mononuclear cell miR-19b-5p, miR- 221, miR-25-5p, and hypertension correlates with an increased heart failure risk in coronary heart disease patients.

Authors:  Yuan Yao; Tao Song; Gang Xiong; Zhaogui Wu; Qi Li; Hao Xia; Xuejun Jiang
Journal:  Anatol J Cardiol       Date:  2018-08       Impact factor: 1.596

8.  Prevalence and factors associated with pulmonary arterial hypertension on maintenance hemodialysis patients in Kinshasa, Democratic Republic of Congo: a cross-sectional study.

Authors:  Yannick Mompango Engole; François Bompeka Lepira; Yannick Mayamba Nlandu; Yves Simbi Lubenga; Augustin Luzayadio Longo; Aliocha Nkodila; Jean-Robert Rissassy Makulo; Vieux Momeme Mokoli; Justine Busanga Bukabau; Marie-France Ingole Mboliasa; Evariste Mukendi Kadima; Cedric Kabemba Ilunga; Tresor Swambulu Mvunzi; Nazaire Mangani Nseka; Ernest Kiswaya Sumaili
Journal:  BMC Nephrol       Date:  2020-11-04       Impact factor: 2.388

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.